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Background: Survivin, a member of the inhibitor of apoptosis-protein family suppresses apoptosis and regulates
cell division. It is strongly overexpressed in the vast majority of cancers. We were interested if survivin detected by
immunohistochemistry has prognostic relevance especially for patients of the two soft tissue sarcoma entities
leiomyosarcoma and synovial sarcoma.
Methods: Tumors of leiomyosarcoma (n = 24) and synovial sarcoma patients (n = 26) were investigated for their
expression of survivin by immunohistochemistry. Survivin expression was assessed in the cytoplasm and the
nucleus of tumor cells using an immunoreactive scoring system (IRS).
Results: We detected a survivin expression (IRS > 2) in the cytoplasm of 20 leiomyosarcomas and 22 synovial
sarcomas and in the nucleus of 12 leiomyosarcomas and 9 synovial sarcomas, respectively. There was no significant
difference between leiomyosarcoma and synovial sarcoma samples in their cytoplasmic or nuclear expression of
survivin. Next, all sarcoma patients were separated in four groups according to their survivin expression in the
cytoplasm and in the nucleus: group 1: negative (IRS 0 to 2); group 2: weak (IRS 3 to 4); group 3: moderate (IRS 6
to 8); group 4: strong (IRS 9 to 12). In a multivariate Cox’s regression hazard analysis survivin expression detected in
the cytoplasm or in the nucleus was significantly associated with overall survival of patients in group 3 (RR = 5.7;
P = 0.004 and RR = 5.7; P = 0.022, respectively) compared to group 2 (reference). Patients whose tumors showed
both a moderate/strong expression of survivin in the cytoplasm and a moderate expression of survivin in the
nucleus (in both compartments IRS ≥ 6) possessed a 24.8-fold increased risk of tumor-related death (P = 0.003)
compared to patients with a weak expression of survivin both in the cytoplasm and in the nucleus.
Conclusion: Survivin protein expression in the cytoplasma and in the nucleus detected by immunohistochemistry
is significantly associated with prognosis of leiomyosarcoma and synovial sarcoma patients.
Background
Leiomyosarcoma and synovial cell sarcoma are two of the
most common malignant soft tissue tumors. Despite survi-
val rates have improved in the past two decades due to
advanced treatment with primary radical surgery, along
with chemotherapy and radiation, long term prognosis
continues to be poor. For instance, synovial sarcoma
patients with non-metastatic surgically resected disease
are reported to have a 5-year overall survival and the 5-
year metastasis-free survival of not more than 71% and
51%, respectively [1]. These survival rates did only tend to
result in better outcomes if chemotherapy was performed;
clearly underscoring the absolute need for identification of
prognostic relevant factors. These factors, possibly assist-
ing in prediction of disease specific prognosis, may help to
evaluate the risk for local and systemic recurrence and
allow stratifying patients to different treatment strategies.
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est as it was shown to be strongly overexpressed in a vast
majority of cancers, and it is one of the most tumor-spe-
cific human gene products [2]. Survivin belongs to two
major protein families, the inhibitor of apoptosis and the
chromosomal passenger families thereby playing an
important role for both regulation of cell death and of
cytokinesis [3-7]. Recently, survivin has been considered
as putative stem cell marker (reviewed in [8]). A correla-
tion between survivin detection and prognosis of tumor
patients has been described for many different cancers
(reviewed in [9]). However, there are also reports indicat-
ing survivin expression is a favourable prognostic marker
(reviewed in [10]). Only a few studies investigated the
correlation of survivin protein expression with prognosis
in sarcomas as it has been described as prognostic mar-
ker for osteosarcomas [11-13]. Nuclear localization of
survivin expression was significantly correlated with a
prolonged survival but cytoplasmic staining showed no
correlation with patients’ outcome [11]. In contrast, in
another study, survivin expression was significantly asso-
ciated with the PCNA-labelling index, which was corre-
lated with the histological grades of osteosarcoma [12].
This result rather confirms a role of survivin in inhibiting
apoptosis and affecting tumor progression [13]. We
investigated survivin expression on the RNA level (qRT-
PCR) and on the protein level (ELISA, Western hybridi-
zation) in a group of different soft tissue sarcomas
including a few leiomyosarcomas and synovial sarcomas,
previously. Elevated survivin RNA and protein level were
significantly correlated with a poor prognosis of STS
patients [9,14]. RNA-Expression of survivin and two
other stem cell-associated genes (Hiwi, hTERT) was cor-
related with a 15.5-fold increased risk of tumor-related
death for soft tissue sarcoma patients [15]. There are
only two reports that studied survivin protein expression
in soft tissue sarcomas by immunohistochemistry but
without correlating results with prognosis [16,17]. Caldas
et al. could show that over 80% of primary rhabdomyo-
sarcoma tumors expressed survivin and Tabone-Eglinger
et al. found survivin protein expressed in all investigated
malignant peripheral nerve sheath tumors [16,17]. This
study aimed for the first time to analyse expression of
survivin protein in the soft tissue entities leiomyosarcoma
and synovial sarcoma by immunohistochemistry. In addi-
tion, to evaluate the prognostic impact of survivin-expres-
sion either detected in the cytoplasm or in the nucleus
for leiomyosarcoma and synovial sarcoma patients.
Methods
Patients
Twenty-four leiomyosarcoma and 26 synovial sarcoma
patients were included in this study. All patients gave
written informed consent (Institute of Pathology,
University of Halle; Department of Surgery 1, University
of Leipzig; Institute of Pathology, Charite - University
Medicine, Berlin; Center for Musculoskeletal Surgery,
Charité - University Medicine, Berlin). The study was
approved by the Local Ethics Committee from the Char-
ite Berlin (EA2/079/07) and the Ethics Committee from
the Medizinische Fakultät MLU Halle. The research car-
ried out on humans is in compliance with the Helsinki
Declaration. Our study group included 21 males and 29
female patients. The tumors were classified according to
the van Unnik grading system, and the UICC guidelines
[18,19]. An overview of clinical and patho-histological
data of the leiomyosarcoma and the synovial sarcoma
patients is given in Table 1.
Immunohistochemical detection
Immunohistochemical detection was performed as pre-
viously described [20,21]. Briefly, the antibody AF886
(RD Systems; Bad Nauheim, Germany, 1:400) was
applied to detect survivin protein. Stained specimens
were viewed at an objective magnification of ×100 and
×200 by two investigators (HJH and CH). Expression of
survivin was determined in the nucleus and in the cyto-
plasm by assessing semi-quantitatively the percentage of
marked tumor cells and the staining intensity. The per-
centage of positive cells was rated as follows: 1, 1-10%
positive cells; 2, 11-50%; 3, 51-80%; and 4, > 80% posi-
tive cells. Staining intensity was scored as 1, weak; 2,
moderate, and 3, intensive. Scores for percentage of
positive cells and scores for expression intensities were
multiplied to calculate an immunoreactive score (IRS)
[22]; 0-2 = no staining; 3-4 = weak staining; 6-8 = mod-
erate staining; 9-12 = strong staining. We separated the
sarcoma patients according to their cytoplasmic expres-
sion of survivin in 25% percentile groups: group 1: IRS 0
to 2 (n = 8); group 2: IRS 3 to 4 (n = 15); group 3: IRS 6
to 8 (n = 19); group 4: IRS 9 to 12 (n = 8). To investi-
gate the possibility of an additive effect of cytoplasmic
and nuclear expression of survivin on survival we
arranged the patients into three groups. In group 1 are
all patients (n = 6) whose tumors showed a weak stain-
ing of survivin both in the cytoplasm and in the nucleus.
In group 2 (n = 35) are all remaining patients; but
patients of group 3 (n = 9) with a moderate or strong
survivin staining in the cytoplasm and a moderate survi-
vin expression in the nucleus (in both compartments
survivin expression showed an immunoreactive score =
6; Table 2). As negative control slides without addition
of primary antibody were included for each staining.
Statistical analyses
Statistical analyses were performed with the SPSS 17.0
software package (SPSS Inc., Chicago, IL). Associations
between immunohistochemical stainings and clinical
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Page 2 of 7Table 1 Clinical and immunohistochemical data for leiomyosarcoma and synovial sarcoma patients
Characteristics Cases Survivin cytoplasm Survivin nucleus
IRS 0-2 3-4 6-8 9-12 0-2 3-4 6-8
Staining negative weak moderate strong negative weak moderate
No. 50 8 15 19 8 29 10 11
Sex
Male 21 4 6 8 3 14 4 3
Female 29 4 9 11 5 15 6 8
Histological subtype
Leiomyosarcoma 24 4 9 10 1 12 8 4
Synovial sarcoma 26 4 6 9 7 17 2 7
Tumor grade
I 511 2 1 31 1
II 21 5 2 10 4 11 6 4
III 24 9 5 7 3 15 3 6
Tumor stage
stage I 5 0 1 3 1 2 2 1
stage II 22 5 3 11 3 15 2 5
stage III 17 2 8 5 2 9 4 4
stage IV 6 1 3 0 2 3 2 1
Complete resection
radical (R0) 38 5 11 15 7 23 7 8
not radical (R1) 12 3 4 4 1 6 3 3
Localization
extremities 33 6 10 10 7 18 7 8
trunc wall 3 0 2 0 1 2 0 1
head/neck 2 1 0 1 0 2 0 0
abdomen/retro- 12 1 3 8 0 7 3 2
peritoneum
Patients follow-up
alive 18 2 6 7 3 10 6 2
dead 32 6 9 12 5 19 4 9
Table 2 Multivariate Cox’s regression hazard analyses
Survivin protein-level Cytoplasm Nucleus
N R RP NR RP
Svv weak (IRS = 3-4) 15 reference 10 reference
Svv negative(IRS = 0-2) 8 4.2 0.055 29 3.1 0.110
Svv moderate (IRS = 6-8) 19 5.7 0.004 11 5.7 0.022
Svv strong (IRS = 9-12) 8 2.4 0.241 none
Combined Svv protein levels
Svv cytopl. & nucleus weak (IRS = 3-4)
1 6 reference
Svv all other cases 35 9.4 0.024
Svv cytopl. & nucleus moderate+strong (IRS ≥ 6)
2 9 24.8 0.003
Correlation of survivin expression in cytoplasm and/or nucleus with prognosis of leiomyosarcoma and synovial sarcoma patients.
Significant results are in bold face;
1Survivin expression both in cytoplasm and in nucleus weak (all IRS = 3-4);
2Survivin expression in cytoplasm moderate or
strong and survivin expression in nucleus moderate (all IRS ≥ 6)
Abbreviations: Svv-survivin; IRS-immunoreactive score; cytopl.-cytoplasma
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2-test. Correlation of
expression of survivin with survival was determined in
multivariate Cox’s regression hazard models (adjusted to
tumor stage, tumor localization and type of tumor
resection). A p-value of less than 0.05 was considered as
statistically significant.
Results
Survivin expression in leiomyosarcoma and synovial
sarcoma
The expression of survivin in the leiomyosarcoma speci-
mens (n = 24) was negative in four, weak in nine, moder-
ate in ten and strong in one cases in the cytoplasm and it
was negative in 12, weak in eight, and moderate in four
cases in the nucleus, respectively (Table 1; Fig.1). We
detected in the synovial sarcoma samples (n = 26) a sur-
vivin expression that was negative, weak, moderate or
strong in four, six, nine and seven cases in the cytoplasm
and that was negative, weak or moderate in 17, two or
seven cases, respectively (Table 1; Fig.1). Although, the
number of more strongly stained specimens is somewhat
higher for synovial sarcomas there was no significant dif-
ference in survivin expression between leiomyosarcomas
and synovial sarcomas. Therefore, we combined cases of
both tumor entities for further statistical analyses. How-
ever, future studies in a larger number of leiomyosarco-
mas and synovial sarcomas have to validate the decision
to combine both sarcoma entities in statistical analysis.
An association between cytoplasmic and nuclear expres-
sion of survivin as trend was found (P = 0.061; chi
2-test).
Correlation of survivin expression with clinical
data and prognosis
Expressions of survivin both in the cytoplasm and in the
nucleus were significantly associated with the prognosis of
leiomyosarcoma and synovial sarcoma patients in multi-
variate Cox’s regression hazard analyses (adjusted to
tumor stage, tumor localization and type of tumor resec-
tion). Patients whose tumors expressed survivin in the
cytoplasm moderately possessed a 5.7-fold increased risk
of tumor-related death (P = 0.004) compared to patients
with tumors, that showed a weak expression of survivin
(Table 2; Fig. 2A). Expression in the nucleus was again for
the patients whose tumors carried a moderate survivin
expression associated with a significantly increased risk of
tumor-related death (RR = 5.7; P = 0.022; Table 2;
Fig. 2B). Next, we studied the possibility of an additive
effect of cytoplasmic and nuclear expression of survivin
on survival. Patients of group 3 with a moderate or strong
survivin staining in the cytoplasm and a moderate survivin
expression in the nucleus possessed an additive signifi-
cantly increased risk of tumor-related death (24.8-fold; P
= 0.003; Table 2, Fig. 2C) compared to patients (group1)
with a weak expression of survivin both in cytoplasm and
nucleus in their tumors. In a Kaplan-Meier analysis
patients of group 3 survived on average 29 months
whereas patients in group 1 had an average survival time
of 73 months but this was not significant because of the
limited number of patients in both groups (P = 0.17; data
not shown).
Discussion
Detection of survivin by immunohistochemistry allows
distinguishing between survivin expression in the two sub-
cellular pools (cytoplasmic and nuclear). Survivin expres-
sion in the cytoplasm could be associated with its control
function of cell survival (inhibitor of apoptosis) whereas
nuclear staining may rather promote cell proliferation
[19]. We investigated both cytoplasmic and nuclear
expression of survivin in the soft tissue sarcoma entities
leiomyosarcoma and synovial sarcoma. Although, a some-
what higher expression of survivin in synovial sarcomas
compared with leiomyosarcomas was detected this differ-
ence was not significant. Therefore, we combined tumor
samples of both entities for our prognostic evaluations.
Both a moderate expression of survivin in the cytoplasm
and in the nucleus was correlated with the poorest prog-
nosis of these soft tissue sarcoma patients (RR = 5.7).
Remarkably, the patient group with moderate expression
of survivin in their tumors includes a higher proportion of
retroperitoneal leiomyosarcomas with a poor survival.
However, a negative expression of survivin both in the
cytoplasm and in the nucleus was, although not signifi-
cantly, associated with a poor outcome compared with
patients whose tumors showed a weak expression of
Figure 1 Immunohistochemical detection of survivin. Detection
of survivin in leiomyosarcoma in cytoplasm (A) and in cytoplasm
+nuclei (B) Detection of survivin in synovial sarcoma in cytoplasm
(C) and in cytoplasm+nuclei (D) (magnification 200×)
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Page 4 of 7Figure 2 Multivariate Cox’s regression hazard analysis.S u r v i v i ne x p r e s s i o ni nt h ec y t o p l a s ma n d / o ri nn u c l e u si sc o r r e l a t e dw i t hap o o r
prognosis for leiomyosarcoma and synovial sarcoma patients. Survivin expression in the cytoplasm (A) and in the nucleus (B) A: Upper curve:
weak expression; 2
nd curve: strong expression; 3
rd curve: negative expression and lower curve: moderate expression of survivin in the cytoplasm.
B: Upper curve: weak expression; 2nd curve: negative expression and lower curve: moderate expression of survivin in the nucleus. Combined
expression of survivin in the cytoplasm and in the nucleus (C) C: Upper curve: Survivin expression both in cytoplasm and in nucleus weak (all IRS
= 3-4); 2
nd upper curve: all other cases and lower curve: Survivin expression in cytoplasm moderate or strong and survivin expression in nucleus
moderate (all IRS ≥ 6).
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Page 5 of 7survivin. This finding could be of relevance in planning
therapeutic strategies that target survivin. When we com-
b i n e ds u r v i v i ne x p r e s s i o ni nt h ec y t o p l a s ma n di nt h e
nucleus patients whose tumors showed an elevated expres-
sion in both compartments carried an additive increased
risk of tumor related death (RR = 24.8; P = 0.003) com-
pared to patients with a weak expression of survivin in
their tumors. We suggest that survivin expression both in
the cytoplasm and in the nucleus should be considered
together to evaluate its impact on prognosis.
Recently, the export of nuclear survivin to the cyto-
plasm could be shown as causal for the survivin-
mediated protection against chemo- or radiotherapy-
induced apoptosis [23]. Therefore, investigation of survi-
vin expression in different sarcoma entities may have
importance for future therapy options. Recently, treat-
ment of rhabdomyosarcoma xenografts with Survivin-
shRNA-encoding plasmids showed greater than 70%
reduction in growth when compared with control
injected tumors [16]. There are several strategies under
investigation to target survivin include antisense oligo-
nucleotides, siRNA, ribozymes, immunotherapy and
small molecular weight molecules [24]. The translation
of these findings to the clinic is currently ongoing with
a number of phaseI/II clinical trials including antisense
oligonucleotide LY2181308, the low molecular weight
molecule inhibitor YM155 and survivin-directed auto-
lougous cytotoxic T lymphocytes [24] The latter strat-
egy, i.e. survivin peptide vaccination w/o different
combination therapies has been or is recently applied in
different phase I/II clinical trials for advanced mela-
noma, myeloma, plasma cell neoplasm, pancreatic,
colon, cervical, breast, oral cancer and renal cell carci-
noma [24-26].
Conclusion
Altogether inhibition of survivin and other stem cell-
associated genes [15] in combination with radio-che-
motherapy and/or immunotherapy may help to improve
sarcoma therapy in the future.
In summary, both cytoplasmic and nuclear expression
of survivin detected by immuno-histochemistry is an
independent prognostic factor for leiomyosarcoma and
synovial sarcoma patients.
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